{"entity":{"id":"stanley-riddell","kind":"person","name":"Stanley R. Riddell","aka":[],"tldr":"Adoptive T-cell therapy pioneer whose defined-composition CAR-T work led to lisocabtagene maraleucel.","summary":"Stanley Riddell is Professor in the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center. An immunologist specialising in T-cell immunotherapy, CAR-T and adoptive cell transfer, he pioneered antigen-specific T-cell transfer for viral infections after transplant and later CD19 CAR-T with defined CD4:CD8 ratios, the basis of Juno Therapeutics and of lisocabtagene maraleucel (Breyanzi). His papers include the report of CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B-cell ALL and the Science paper on restoring viral immunity in immunodeficient humans by adoptive transfer of T cell clones. He now works on CAR design and solid-tumour targets such as ROR1, with relevance to lymphoma and leukaemia.","asOf":"2026-09-08","links":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Stanley%20R.%20Riddell"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Riddell%20SR%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Stanley%20R.%20Riddell"}],"tags":[],"related":[],"cancers":["dlbcl","all-leukemia","cll"],"sections":[],"technologies":["car-t"],"targets":["cd19","ror1"],"drugs":["lisocabtagene-maraleucel"],"companies":[],"institutions":["fred-hutch"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jci"],"dependsOn":[],"notes":[],"role":"Professor, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center","institutionId":"fred-hutch","specialisms":["T-cell immunotherapy","CAR-T","Adoptive cell transfer"],"profiles":[{"label":"Fred Hutch faculty directory","url":"https://www.fredhutch.org/en/faculty-lab-directory.html?q=Stanley%20R.%20Riddell"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Riddell%20SR%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Stanley%20R.%20Riddell"}],"papers":[{"title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","journal":"Journal of Clinical Investigation","year":2016,"url":"https://doi.org/10.1172/JCI85309","doi":"10.1172/JCI85309"},{"title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","journal":"Science","year":1992,"url":"https://doi.org/10.1126/science.1352912","doi":"10.1126/science.1352912"}],"orcid":"0000-0002-4688-9920"},"route":"/people/stanley-riddell/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"ror1","kind":"target","name":"ROR1","route":"/targets/ror1/"}],"drug":[{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/"}],"institution":[{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/"}],"journal":[{"id":"jci","kind":"journal","name":"Journal of Clinical Investigation","route":"/journals/jci/"}]}}